List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Benign Plant Derived Surfactants for Household and Other Applications

    SBC: NATURE'S SECRET SOLUTIONS INC            Topic: 88

    The goal of this project is to demonstrate the feasibility of using renewable plant-based materials to derive biodegradable, environmentally benign, non-toxic surfactants, to replace the chemically synthesized surfactants in use today. Surfactants are a unique class of chemical products that are used in large quantities for a wide variety of detergents, household cleaning products, personal care p ...

    SBIR Phase I 2014 Department of Agriculture
  2. Development of water based 1-methyl cyclopropene formulation for modifying ethylene response of fruit and field crops

    SBC: MIRTECH INC.            Topic: 85

    The objective of this project is to develop a sprayable water-based 1-methylcycopropene (1-MCP) liquid formulation for apple, to manage the undesirable effects of ethylene when the fruits are still attached to the tree and during post-harvest storage. The motivation is to overcome the limitations of current delivery formulations to improve quality and extend the shelf life of fruits, a major imped ...

    SBIR Phase I 2014 Department of Agriculture
  3. THE PURPOSE OF THIS GRANT IS TO SELECT APPROVABLE DRUGS FOR THE TREATMENT OF FOUR ORPHAN DISEASES: SICKLE CELL DISEASE,THALASSEMIA, HEMOCHROMATOSIS, AND ERYTHROPOIETIC PORPHYRIAS.

    SBC: Atmospheric Health Sciences            Topic: N/A

    THE PURPOSE OF THIS GRANT IS TO SELECT APPROVABLE DRUGS FOR THE TREATMENT OF FOUR ORPHAN DISEASES: SICKLE CELL DISEASE,THALASSEMIA, HEMOCHROMATOSIS, AND ERYTHROPOIETIC PORPHYRIAS.FROM THE AVAILABLE WORLD MEDICAL LITERATURE ON THE FOUR DISEASES, DRUGS THAT ARE CLAIMED TO BE EFFECTIVE WILL BE EVALUATED AND CATEGORIZED AS TO THE EXTENT OF CLINICAL TESTING AND ANIMAL EXPERIMENTATION. THE THERAPEUTIC R ...

    SBIR Phase I 1983 Department of Health and Human Services
  4. ADENOSINE DEAMINASE (ADA) AND PURINE NUCLEOSIDE PHOSPHORYLASE (PNP) DEFICIENCIES ARE ASSOCIATED WITH CERTAINIMMUNODEFICIENCIES IN HUMANS.

    SBC: Ert            Topic: N/A

    ADENOSINE DEAMINASE (ADA) AND PURINE NUCLEOSIDE PHOSPHORYLASE (PNP) DEFICIENCIES ARE ASSOCIATED WITH CERTAINIMMUNODEFICIENCIES IN HUMANS. ENZON WILL USE PATENTED METHODOLOGY TO PREPARE THERAPEUTIC MODIFICATIONS OF ADA AND PNP. THE PROCEDURE CONSISTS OF ATTACHMENT OF MONOMETHOXYPOLYETHYLENE GLYCOL (PEG) IN SUFFICIENT AMOUNTS TO ENZYMES TO PRODUCE CONJUGATES THAT ARE ESSENTIALLY NONIMMUNOGENIC AND S ...

    SBIR Phase I 1983 Department of Health and Human Services
  5. Improving Data, Improving Care, Making it Count, Integration Toolkit for Eliminating Double Data Entry

    SBC: Hdox Bioinformatics Inc.            Topic: N/A

    Phase II goals will be to: 1. To develop a production version of an Integration toolkit (ITK) that can deployed at low cost to clinics using spina bifida EMR (to improve the efficiency of their participation in the NSBPR) 2. To pilot the ITK at selected SB-EMR clinics 3. To evaluate the impact of the production version of the ITK The ITK will be developed based on design principles & specifica ...

    SBIR Phase II 2014 Department of Health and Human Services
  6. Innate Defense Regulator Peptide as a Therapeutic for Acute Pneumonic Melioidosis

    SBC: Soligenix, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): This proposal describes development of an immunomodulatory peptide that targets the host defense system for treatment of acute pneumonic melioidosis. The disease is caused by Burkholderia pseudomallei (Bps), a non-spore-forming motile saprophytic bacterium that can be transmitted from the soil to humans by inhalation, through cuts in the skin and by ingestion. ...

    SBIR Phase I 2014 Department of Health and Human Services
  7. Increasing viability of lung organs for transplantation

    SBC: TRIM-EDICINE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): While organ transplantation is a vital last resort therapy to treat patients with end-organ failure of the lung there is a growing waiting list of patients who are eligible for transplants as the number of suitable donor organs fall far short of the demand for these lifesaving procedures. Improving the preservation of donated organs so that a greater percentage ...

    SBIR Phase I 2014 Department of Health and Human Services
  8. TRAIL Upregulation by TIC10 Analogs

    SBC: PROVID PHARMACEUTICALS INC.            Topic: NCI

    Project Summary/Abstract TIC10 (ONC201) is a first-in-class antitumor agent and small molecule inducer of the TRAIL gene which was identified in a high-throughput small molecule library screen in the lab of our collaborator, Dr. Wafik El-Deiry at Penn State University and has been shown to have preclinical efficacy in several difficult-to-treat disease settings that include unmet clinical needs su ...

    SBIR Phase I 2014 Department of Health and Human Services
  9. Development of Novel Fast GPU Monte Carlo and Active Photonics Simulation Softwar

    SBC: SIMPHOTEK, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Photodynamic therapy (PDT) is used for treating a variety of medical conditions including cancer. Even after many years of PDT research and the large-scale use of PDT treatments by physicians, there are many aspects ofPDT, such as quantitative predictions for diffusive light propagation and the kinetics of the light-material interactions, that are not well unde ...

    SBIR Phase I 2014 Department of Health and Human Services
  10. SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer

    SBC: Soligenix, Inc            Topic: NIDCR

    DESCRIPTION (provided by applicant): Oral mucositis has a significant impact on patient quality of life and outcomes during cancer therapy as well as having a significant pharmacoeconomic cost. There are no currently approved drugs to treat oral mucositisin patients with non-hematological malignancies, including head and neck cancer (HNC). Soligenix is developing a new compound, SGX942, a modulat ...

    SBIR Phase I 2014 Department of Health and Human Services

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government